Comparative Pharmacology
Head-to-head clinical analysis: LIQUID E Z PAQUE versus RENO DIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUID E Z PAQUE versus RENO DIP.
LIQUID E-Z-PAQUE vs RENO-DIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Barium sulfate is a radiopaque agent that coats the mucosal surface of the gastrointestinal tract, attenuating X-rays and providing contrast on imaging studies.
RENO-DIP (dipyridamole) is a platelet aggregation inhibitor that inhibits adenosine deaminase and phosphodiesterase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and blocks adenosine reuptake, resulting in vasodilation and inhibition of platelet aggregation.
Oral: 25-50 mL (barium sulfate 60% w/v) as a single dose for upper GI series; for double-contrast studies, 100-200 mL (barium sulfate 250% w/v) as a single dose. Rectal: For barium enema, 200-300 mL of a 15-20% w/v suspension instilled via enema tube.
Hypertension: initial 10 mg orally once daily, titrate to 40 mg once daily. Heart failure: initial 2.5 mg orally twice daily, titrate to 20 mg twice daily as tolerated.
None Documented
None Documented
Not applicable (non-systemic agent); plasma half-life not clinically relevant.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily fecal (oral route, unabsorbed); negligible renal excretion (<1% as intact drug).
Primarily renal excretion of unchanged drug (70%) via glomerular filtration and active tubular secretion; 20% excreted as metabolites in urine; 10% eliminated in feces via biliary secretion.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent